Activity of Aldehyde-Dehydrogenase in B-Cell and Plasma Cell Subsets of Monoclonal Gammapathy Patients

Pavla Vsianska, Lucie Rihova, Fedor Kryukov, Miroslav Penka, Roman Hajek

1. Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic, 2. Babak Myeloma Group by Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic, 3. Department of Haematonoctology, University Hospital Ostrava and Faculty of Medicine OU, Ostrava, Czech Republic

Multiple myeloma (MM) is characterized by the presence of clonal plasma cells (PC) arising from malignant transformed B-cells. Aldehyde-dehydrogenase (ALDH) is an intracellular enzyme catalysing degradation of aldehydes to protect the cell against a toxic. It is active in hematopoietic stem and progenitor cells and its increased activity was detected also in some types of cancer stem cells.

The aim of this study was monitoring of ALDH activity in B-cell and plasma cell subsets in monoclonal gammapathy patients to identify potential source population of myeloma progenitors.

Bone marrow of 11 newly diagnosed MM and 9 MGUS patients were analysed by 8-color flow cytometry. Identification of CD45-immature, CD45-immature, naive, memory (with/without isotype switch) and switched CD27+ B, as well as plasmablasts and PCs (CD19+PCs, CD19+PCs and CD138-immature PCs) was performed according to expression of surface markers CD38, CD45, CD20, CD138, CD19, CD27 and IgM. Aldefluor assay was used to identify activity of ALDH in individual subsets. Rate of ALDH activity was assessed based on percentage of ALDH positive cells (%pos) and ratio (r) of median fluorescence intensity (MFI) of ALDH and MFI of negative control. Statistical significance of differences in continuous variables among groups of patients was analysed using nonparametric Kruskal-Wallis or Mann-Whitney U test test.

Higher ALDH activity in CD45-immature B in comparison with naïve B was found in both, MM and MGUS according to MFI [1.32 (1.08-1.79) vs. 1.03 (0.72-1.59) and 1.34 (0.7-1.51) vs. 1.12 (0.65-1.18), resp., p<0.05], and in MM also according to %pos [8.0 (4.0-22.6) vs. 1.5 (0.1-2.76), p<0.05]. In MM there was found higher ALDH activity in CD19+PCs, CD19+PCs and CD138-immature PCs compared to naïve B based on MFI [1.27 (0.77-1.64) vs. 1.55 (0.80-2.44); 1.29 (0.66-1.93) and 1.03 (0.72-1.59) resp., p<0.05], as well as %pos [5.9 (1.3-19.7); 19.2 (0.4-52.9); 7.5 (0.4-35.1) and 1.5 (0.1-27.6), resp., p<0.05]. No difference was found among PC subsets and also between individual PC subsets and CD45-immature B. There was found higher ALDH activity in CD19+PCs compared with naïve B based on both MFI and as %pos [1.52 (1.3-1.87) vs. 1.12 (0.65-1.18); 17.1 (12.6-43.8) vs. 3.1 (1.2-8.2), p<0.05], while no difference was found between CD19+PCs and naïve B in MGUS. Moreover there was found higher ALDH activity in CD19+PCs compared with CD19+PCs based on MFI [1.52 (1.13-1.87) vs. 1.18 (0.77-1.34) p<0.05], as well as %pos [17.1 (12.6-43.8) vs. 3.3 (1.3-11.5) p<0.05].

Increased ALDH activity in immature B-cells is probably caused by presence of very immature cells which retain some properties of stem cells. The rate of ALDH activity in CD19+PC subsets is same as in immature B-cells, so it could indicate the presence of myeloma initiating cells exactly among these PC subsets.

Supported by: IGAT2425 and GACR P304/10/1395.

233/B95

A Shape-Based Study of Platelet Activation with the Scanning Flow Cytometry

Alexander Moskalensky1,2, Maxim Yurkin1,2, Dmitry Strokotov1, Valeri Maltev1,2

1. Laboratory of cytometry and biokinetics, Voevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, Russia, 2. Physics department, Novosibirsk State University, Novosibirsk, Russia

Background: Blood platelets play a central role in hemostasis and are involved in many diseases, including thrombosis, hemorrhage, inflammation, and cancer. Platelet activation occurs normally in response to vessel wall injury or other physiological stimuli. It is very dangerous when become inappropriate, i.e., when platelets activate spontaneously or due to low dose of agonist. There are several approaches to assess the strength of platelet activation measuring the fraction of activated platelets with surface receptors labeling and the flow cytometry. We proposed an alternative technique based on the measurement of platelet shape, also being a marker of platelet activation (Moskalensky et al, J. Biomed. Opt. 18, 017001, 2013). In current work, we present experimental data obtained for different patients using this technique.

Methods: We use the scanning flow cytometry, which is based on the measurement of angle-resolved light-scattering profiles (LSPs) of individual cells and on the solution of the inverse light-scattering (ILS) problem.

We measure LSPs with the Scanning Flow Cytometer fabricated by CytoNova Ltd. (Novosibirsk, Russia, http://cyto.kinetics.nsc.ru/). The solution of ILS problem is based on fitting an experimental LSP with theoretical ones, modeling platelets as oblate spheroids. The measurement of platelets size and shape and hence the fraction of activated cells is possible without labeling and/or fixation. This reduces the sample preparation to the sole dilution of the whole blood or platelet plasma. Also an agonist (ADP or collagen) is added prior to measurement to induce platelet activation.

Results: The study of platelets with the scanning flow cytometry was performed for several patients. The platelets volume distributions determined by the solution of the ILS problem agree well with the results of standard analysis. The determined platelet shape show bi-modal distribution, corresponding to presence of resting and activated platelets. The ratio between resting and activated cells correlates well with the dose of agonist and varies from patient to patient.

Since no fixation step is required, a gradual transition of platelets from one state to another is visible over time, which can also be used for characterization of the platelet function. This transition occurs in first minutes after addition of agonist.

Conclusions: The shape-based approach to detect activated platelets can assist in diagnostics of platelet-associated disorders. It does not require labeling step, which facilitates rapid tests in clinical setting. Novel parameters, such as shape distribution and the time-
dependent activation course, are obtained using this approach. Further clinical studies are needed to correlate different disorders and these parameters.

234/B96

Flow Cytometry Analysis of Plasma Cell Phenotype in Extramedullary Relapse of Multiple Myeloma

Lucie Rihova1,2, Pavla Viasnska1,2, Hana Svachova2, Renata Bezdekova1,2, Petra Kucerova1, Renata Suska1, Sabina Sevcikova1,2, Ludek Pour3,4, Roman Hajek3,4

1Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic, 2Babay Myeloma Group by Department of Pathological Physiology, Masaryk University, Brno, Czech Republic, 3Department of Internal Medicine - Haematology-oncology, University Hospital Brno, Brno, Czech Republic, 4Department of Haematology-oncology, University Hospital Ostrava, Ostrava, Czech Republic

Background: Multiple myeloma (MM) is the second most common haematological malignancy in the world which is characteristic by a presence of clonal plasma cells (PCs). The introduction of new drugs (thalidomide, bortezomib, revlimid) has dramatically improved survival of MM patients, but MM still remains an incurable disease. Unfortunately, an increase in the incidence of extramedullary relapse of MM (EM), an aggressive mostly resistant entity with abysmal prognosis for patients has been reported. EM can affect any area of tissue - soft tissue involvement can be with or without relationship to bone marrow (BM). Finding a marker and/or phenotype allowing predict a risk of EM formation could help to improve treatment strategies and prolong patient life.

Aim: Analysis and comparison of PC phenotype in bone marrow and tumor tissue (TU) of EM cases.

Subjects and methods: There were analysed 28 MM patients (median age 62 years) with confirmed EM. Analysis of 25 bone marrows and 19 tumor tissues was done by polychromatic flow cytometry. Phenotype of CD38+CD138+ PCs was analysed using CD19, CD20, CD27, CD28, CD44, CD56, CD81, CD117 and nestin. PCs from BM and/or TU were considered positive for given marker when its expression on PCs was higher than 20%.

Results: There were detected CD38+CD138+ PCs in all BM samples and in almost all TU samples (except 1 sample probably acquired not from tumor site). PC infiltration was significantly higher in TU then in BM [median of infiltration 51.7% (range 0.9-43.3%) vs. 1.5% (0.01-93.9%); p<0.001]. Although TU PCs have relatively similar phenotype like BM PCs, there was found significant decrease in median of expression of CD27 [18.1% in BM (range 0.5-92.0%) vs. 1.8% in TU (0.0-63.0); p=0.01] and also in number of CD27+ PCs [12/24 (50%) in BM vs. 2/16 (12.5%) in TU]. Moreover, no presence of CD19+ normal PCs on tumor PCs was found even if mixture of CD19+ and CD19- PCs was detected in BM (p<0.001), EM PCs (BM and/or TU) were almost negative for CD20 (5.3% CD20+ PCs in BM and 6.3% in TU) and CD81 (12.5% CD81+ PCs in BM and 14.3% in TU). On the other hand, EM PCs usually express nestin, a marker of extramedullary spread, which was found in 81.8% BM PCs and 100% of TU PCs; and EM PCs were always positive for CD44, a glycoprotein involved in cell-cell interactions, cell adhesion and migration. Adhesion molecule CD56, which is considered as a marker of extramedullary spread, was found on majority of EM PCs (70.8% CD56+ PCs in BM and 75.0% in TU).

Conclusion: Flow cytometry analysis of BM PCs allows to identify a phenotype profile (CD20+CD27+CD81+CD44+nestin+) related to possible extramedullary involvement in multiple myeloma.

Acknowledgements: This work was supported by MSM0021622434, IGA NT12425-4, IGA NT12130-4 and GACR P304/10/1395 grants.